Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor γ activation

International Journal of Molecular Medicine

Volumn 25, Issue 5, 2010, Pages 729-734

  Zhang, Yihua ^a   Luo, Zhidan ^b   Ma, Liqun ^b   Xu, Qiang ^a   Yang, Qihong ^a   Si, Liangyi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycosylation end products; Lipid accumulation; Macrophage; Peroxisome proliferator activated receptor ; Receptor for advanced glycosylation end products; Resveratrol

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CHOLESTEROL; GW 6471; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOLYSIS; DIABETES MELLITUS; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; HOMEOSTASIS; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; STEROL ANALYSIS; UPREGULATION;

ADENYLATE KINASE; ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MACROPHAGES; PPAR GAMMA; RECEPTORS, IMMUNOLOGIC; STILBENES;

EID: 77951737083     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm-00000398     Document Type: Article

References (30)

1. Beckman JA, Creager MA and Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002.
2. King H, Aubert RE and Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431, 1998.
3. Wu JT: Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal 7: 252-255, 1993.
4. Yamagishi S, Nakamura K, Matsui T, Noda Y and Imaizumi T: Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14: 487-495, 2008. (Pubitemid 351516853)
5. Bro S, Flyvbjerg A, Binder CJ, et al: A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 201: 274-280, 2008.
6. Csiszar A and Ungvari Z: Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-α signaling. Am J Physiol Heart Circ Physiol 295: H475-H476, 2008.
7. Ge J, Jia Q, Liang C, et al: Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 25: 2157-2163, 2005. (Pubitemid 41416315)
8. Cuchel M and Rader DJ: Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113: 2548-2555, 2006.
9. Shashkin P, Dragulev B and Ley K: Macrophage differentiation to foam cells. Curr Pharm Des 11: 3061-3072, 2005.
10. Iwashima Y, Eto M, Hata A, et al: Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277: 368-380, 2000.
11. Xanthis A, Hatzitolios A, Fidani S, Befani C, Giannakoulas G and Koliakos G: Receptor of advanced glycation end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes. Angiology 60: 772-779, 2009.
12. Passarelli M, Tang C, McDonald TO, et al: Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54: 2198-2205, 2005. (Pubitemid 40911284)
13. Isoda K, Folco EJ, Shimizu K and Libby P: AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 192: 298-304, 2007. (Pubitemid 46726331)
14. Sadruddin S and Arora R: Resveratrol: biologic and therapeutic implications. J Cardiometab Syndr 4: 102-106, 2009.
15. Zang M, Xu S, Maitland-Toolan KA, et al: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55: 2180-2191, 2006. (Pubitemid 44743614)
16. Park DW, Baek K, Kim JR, et al: Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41: 171-179, 2009.
17. Ulrich S, Loitsch SM, Rau O, et al: Peroxisome proliferator-activated receptor γ as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 66: 7348-7354, 2006. (Pubitemid 44197718)
18. Cheng G, Zhang X, Gao D, Jiang X and Dong W: Resveratrol inhibits MMP-9 expression by up-regulating PPAR γ expression in an oxygen glucose deprivation-exposed neuron model. Neurosci Lett 451: 105-108, 2009.
19. Kennedy A, Overman A, Lapoint K, et al: Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol. J Lipid Res 50: 225-232, 2009.
20. Wang K, Zhou Z, Zhang M, et al: Peroxisome proliferatoractivated receptor γ down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317: 37-43, 2006.
21. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K and Okuda S: Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun 385: 269-272, 2009.
22. Yoshida T, Yamagishi S, Nakamura K, et al: Telmisartan inhibits AGE-induced C-reactive protein production through down-regulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation. Diabetologia 49: 3094-3099, 2006. (Pubitemid 44730314)
23. Ouimet M, Wang MD, Cadotte N, Ho K and Marcel YL: Epoxycholesterol impairs cholesteryl ester hydrolysis in macrophage foam cells, resulting in decreased cholesterol efflux. Arterioscler Thromb Vasc Biol 28: 1144-1150, 2008.
24. Zhang LL, Yan Liu D, Ma LQ, et al: Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 100: 1063-1070, 2007.
25. Mizutani K, Ikeda K, Nishikata T and Yamori Y: Phyto-estrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Hypertens 18: 1833-1840, 2000.
26. Mizutani K, Ikeda K and Yamori Y: Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 274: 61-67, 2000. (Pubitemid 30496757)
27. Ma L, Gao HQ, Li BY, Ma YB, You BA and Zhang FL: Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor γ. J Cardiovasc Pharmacol 49: 293-298, 2007. (Pubitemid 46855123)
28. Li AC, Binder CJ, Gutierrez A, et al: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, beta/delta, and γ. J Clin Invest 114: 1564-1576, 2004. (Pubitemid 40385547)
29. Moore KJ, Rosen ED, Fitzgerald ML, et al: The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 7: 41-47, 2001.
30. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA and Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998. (Pubitemid 28180857)